Rubius Therapeutics is a clinical-stage biopharmaceutical company, engaged in developing cellular medicines called Red Cell Therapeutics, or RCTs. Co. has developed a platform, RED PLATFORM, to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies for the potential treatment of cancer and autoimmune diseases. Co. is developing RCT product candidates based on two therapeutic modalities, which include immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Co. has developed RTX-240 and RTX-224, an RCT product candidate for the treatment of patients suffering from solid tumors. The RUBY stock yearly return is shown above.
The yearly return on the RUBY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RUBY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|